6 Result(s)
within
Christoph W. M. Reuter
-
Article
Open AccessPrognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unkno...
-
Article
Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia
Transforming mutations in RAS genes are commonly found in human malignancies, including myeloid leukemias. To investigate the incidence, spectrum, and distribution of activating K- and N-RAS mutations in cytogene...
-
Article
Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells
Deregulation of Ras/ERK signaling in myeloid leukemias makes this pathway an interesting target for drug development. Myeloid leukemia cell lines were screened for idarubicin-induced apoptosis, cell-cycle prog...
-
Article
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may be effective in combination with doceta...
-
Article
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma
Metastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy. Combined data for a variety of immunotherapies resulted in an overall chance of partial (PR) or complete remission (CR) of only ...
-
Article
Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias
Although there has been significant progress in acute myeloid leukemia (AML) treatment in younger adults during the last decade, standard induction therapy still fails to induce remission in up to 40% of AML p...
